USPTO Deadlines
Application History
21 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Mar 9, 2012 | UNDN | O | UNDELIVERABLE MAIL - NO ACTION TAKEN | Loading... |
Feb 13, 2012 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
Feb 13, 2012 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
Jul 26, 2011 | UNDN | O | UNDELIVERABLE MAIL - NO ACTION TAKEN | Loading... |
Jul 22, 2011 | UNDN | O | UNDELIVERABLE MAIL - NO ACTION TAKEN | Loading... |
Jul 12, 2011 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
May 18, 2011 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
May 17, 2011 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
May 5, 2011 | WOAR | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | Loading... |
May 5, 2011 | WOAG | I | WITHDRAWAL OF ATTORNEY GRANTED | Loading... |
Apr 9, 2011 | ALIE | A | ASSIGNED TO LIE | Loading... |
Apr 9, 2011 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
Mar 29, 2011 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
Mar 29, 2011 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
Mar 29, 2011 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
Mar 29, 2011 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
Mar 29, 2011 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Mar 21, 2011 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Dec 31, 2010 | MPMK | O | NOTICE OF PSEUDO MARK MAILED | Loading... |
Dec 30, 2010 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Dec 24, 2010 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ards), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (svt), adenosine stress tests, infantile respiratory distress syndrome (infantile rds), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (copd), as well as cancers including leukemias, lymphomas, carcinomas, and the like, e.g., colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, e.g., cancers which metastasized to the lung(s), breast, liver and prostate
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
EPIGENESIS
Classification
International Classes
005